XTAL Pi Included in MSCI China Index, Signaling Global Recognition of Its Growth Potential

Beijing time, November 6th, early morning, MSCI, a globally renowned index company, announced the index review results for November 2025.XtalPi, an AI and robotics-driven innovator in new drug and new material discovery（2228.HK）Selected for inclusion in MSCI's most prominent flagship index – the MSCI China Index.This adjustment is based on the results of its semi-annual index review in November and will officially take effect after the market closes on November 24, 2025.

MSCI China Index Adds 26 New Stocks This Time, Including Multiple Resource Stocks and Technology Companies in Artificial Intelligence, Robotics, Semiconductors, and High-End Manufacturing. Entering the MSCI China Index Means Becoming Part of the MSCI Global Standard Index Series, Thereby Attracting Significant Passive Fund Tracking.

The MSCI China Index is one of the key benchmarks for measuring the performance of large and mid-cap companies in China, widely tracked and referenced by global institutional investors. The selection of its constituent stocks is based on objective quantitative metrics, including market capitalization, free float, liquidity, and market investability. Being included in this index indicates that XtalPi has met stringent international standards in terms of market capitalization, market representation, and liquidity, and the company's investment value and growth potential have gained authoritative recognition from the global capital markets.

XtalPi is an innovative R&D platform that deeply integrates quantum physics, artificial intelligence, and large-scale standardized experimental robotics. As a pioneer in the field of Scientific Intelligence (AI for Science), XtalPi has established partnerships with over 300 international enterprises, innovative companies, and research institutions. The company achieved profitability in the first half of 2025, with business areas covering new drug development, energy, agriculture, new materials, novel chemicals, and consumer products. XtalPi is one of the few AI-driven R&D platforms in the industry to have secured high-value collaborations with top international pharmaceutical companies in both AI small-molecule drug and AI biologics research. Among the world’s top 20 largest pharmaceutical companies, 17 are clients of XtalPi.

The inclusion in the MSCI China Index this time is a positive affirmation of XtalPi's performance in the secondary market, its business fundamentals, and future prospects. The company will take this as an opportunity to continue focusing on the construction of core scientific and technological innovation capabilities, consolidate and accelerate the expansion of commercial achievements, create greater value for global customers and partners, and bring sustainable long-term returns to investors.